Pulmatrix (PULM) Earns News Sentiment Score of 0.31

Media coverage about Pulmatrix (NASDAQ:PULM) has trended positive this week, according to Accern Sentiment Analysis. The research group identifies positive and negative news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Pulmatrix earned a news sentiment score of 0.31 on Accern’s scale. Accern also gave headlines about the biotechnology company an impact score of 0 out of 100, indicating that recent news coverage is extremely unlikely to have an impact on the stock’s share price in the near future.

Insider Buying and Selling by Quarter for Pulmatrix (NASDAQ:PULM)

Shares of Pulmatrix (NASDAQ PULM) traded up 2.08% during mid-day trading on Tuesday, reaching $2.45. The company’s stock had a trading volume of 151,369 shares. Pulmatrix has a 12 month low of $0.50 and a 12 month high of $6.98. The firm’s market cap is $46.85 million. The company has a 50-day moving average of $2.63 and a 200-day moving average of $2.54.

Pulmatrix (NASDAQ:PULM) last issued its quarterly earnings data on Friday, May 5th. The biotechnology company reported ($0.21) earnings per share (EPS) for the quarter. Pulmatrix had a negative return on equity of 164.91% and a negative net margin of 3,328.91%. On average, analysts predict that Pulmatrix will post ($4.13) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This news story was originally published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this news story on another domain, it was copied illegally and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this news story can be read at https://sportsperspectives.com/2017/06/20/pulmatrix-pulm-earns-news-sentiment-score-of-0-31.html.

Pulmatrix Company Profile

Pulmatrix, Inc is a clinical stage biopharmaceutical company developing inhaled therapies to address serious pulmonary disease. The Company’s product pipeline is focused on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with lung disease, including cystic fibrosis.

Receive News & Ratings for Pulmatrix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply